Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication-Reference-Cited by-同舟云学术

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Published:2015-10 Issue:10 Volume:10 Page:e97-e99
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Baik Christina S.,Wu David,Smith Christina,Martins Renato G.,Pritchard Colin C.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference6 articles.

1. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens;Pritchard;J Mol Diagn,2014

2. Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain;Ozer;Oncogene,2010

3. Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation;Furgason;Mutagenesis,2014

4. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial;Garassino;Lancet Oncol,2013

5. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA);Kawaguchi;J Clin Oncol,2014

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR kinase domain duplication in lung adenocarcinoma with systemic and intracranial response to a double-dose of furmonertinib: a case report and literature review;Frontiers in Oncology;2024-06-21

2. Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors;The Oncologist;2024-05-31

3. Expanding the Clinical Utility of Targeted RNA Sequencing Panels beyond Gene Fusions to Complex, Intragenic Structural Rearrangements;Cancers;2023-09-02

4. Organoid drug screening report for a non-small cell lung cancer patient with EGFR gene mutation negativity: A case report and review of the literature;Frontiers in Oncology;2023-02-16

5. Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer;Biomolecules;2023-01-20